Greenberg H E, Rapoport D M, Rothenberg S A, Kanengiser L A, Norman R G, Goldring R M
Department of Medicine, New York University Medical Center, New York 10016.
Am Rev Respir Dis. 1991 Jun;143(6):1282-7. doi: 10.1164/ajrccm/143.6.1282.
Defense of ventilatory homeostasis against recurrent hypercapnia, hypoxia, and acidosis resulting from apnea in obstructive sleep apnea syndrome (OSAS) is dependent on compensatory mechanisms operative between episodes of airway obstruction. This investigation was designed to examine whether endogenous opiate activity modulates the compensatory ventilatory response to apnea in OSAS. Polysomnography and quantitative measurement of tidal volume was performed in 12 patients with moderate to severe OSAS during a morning nap study before and after intravenous administration of 10 mg of naloxone. Apnea index was not significantly altered. There was a small but significant shortening of apneas (postnaloxone apnea duration, 91.2% of prenaloxone; p = 0.002 by ANOVA). Tidal volume of the first postapnea breath and minute ventilation extrapolated from the first two postapnea breaths, but not frequency, increased significantly after naloxone (postnaloxone first breath volume, 112.7% of prenaloxone value [p = 0.03], with a similar increase for minute ventilation, 115.1% [p = 0.007]). The volume of the first postapnea breath was correlated with the duration of the previous apnea, both before (r = 0.59, p = 0.0001) and after naloxone. Despite this, analysis of covariance with apnea duration as the covariate confirmed a significant independent increase in postapnea breath volume after naloxone (p = 0.001). Naloxone also altered sleep architecture, increasing percent time awake during the study period (prenaloxone, 36.3 +/- 15.6%; postnaloxone, 56.7 +/- 22.4%; p = 0.0003) and decreasing total sleep time and percent time in Stage 1. Furthermore, naloxone increased continuity of awake periods (mean length of awake periods increased from 27.0 +/- 8.4 to 66.0 +/- 66.6 s after naloxone, p = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
阻塞性睡眠呼吸暂停综合征(OSAS)中,针对呼吸暂停导致的反复高碳酸血症、低氧血症和酸中毒,呼吸稳态的防御依赖于气道阻塞发作期间起作用的代偿机制。本研究旨在探讨内源性阿片活性是否调节OSAS中对呼吸暂停的代偿性通气反应。在12例中重度OSAS患者上午小睡研究期间,静脉注射10mg纳洛酮前后进行多导睡眠图检查和潮气量定量测量。呼吸暂停指数无显著改变。呼吸暂停有小幅但显著的缩短(纳洛酮后呼吸暂停持续时间,为纳洛酮前的91.2%;方差分析p = 0.002)。纳洛酮后,首次呼吸暂停后呼吸的潮气量以及从前两次呼吸暂停后呼吸推算出的分钟通气量显著增加,但呼吸频率未增加(纳洛酮后首次呼吸量,为纳洛酮前值的112.7% [p = 0.03],分钟通气量有类似增加,为115.1% [p = 0.007])。首次呼吸暂停后呼吸的量与前一次呼吸暂停的持续时间相关,纳洛酮前后均如此(r = 0.59,p = 0.0001)。尽管如此,以呼吸暂停持续时间为协变量的协方差分析证实纳洛酮后呼吸暂停后呼吸量有显著的独立增加(p = 0.001)。纳洛酮还改变了睡眠结构,增加了研究期间的清醒时间百分比(纳洛酮前,36.3±15.6%;纳洛酮后,56.7±22.4%;p = 0.0003),并减少了总睡眠时间和1期睡眠时间百分比。此外,纳洛酮增加了清醒期的连续性(纳洛酮后清醒期平均长度从27.0±8.4秒增加到66.0±66.6秒,p = 0.05)。(摘要截断于250字)